Bernstein: Eli Lilly raises full-year revenue guidance as weight-loss drug demand stays strong, while new oral drug gets off to a slower start
Third-quarter revenue exceeded market consensus by about 1.9 billion dollars, with a beat of about 1 billion dollars even after excluding favorable items. Bernstein raised its full-year revenue forecast while monitoring one-time revenue, channel pricing and the pace of the Foundayo rollout.